» Articles » PMID: 26993100

Apoptosis-induced Ectodomain Shedding of Hypoxia-regulated Carbonic Anhydrase IX from Tumor Cells: a Double-edged Response to Chemotherapy

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2016 Mar 20
PMID 26993100
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin.

Methods: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay.

Results: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness.

Conclusions: These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression.

Citing Articles

Carbonic Anhydrase IX in Tumor Tissue and Plasma of Breast Cancer Patients: Reliable Biomarker of Hypoxia and Prognosis.

Rezuchova I, Bartosova M, Belvoncikova P, Takacova M, Zatovicova M, Jelenska L Int J Mol Sci. 2023; 24(5).

PMID: 36901756 PMC: 10002431. DOI: 10.3390/ijms24054325.


ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non‑redundantly to ADAM17.

Zatovicova M, Kajanova I, Takacova M, Jelenska L, Sedlakova O, Labudova M Oncol Rep. 2022; 49(2).

PMID: 36524367 PMC: 9813547. DOI: 10.3892/or.2022.8464.


Immunomodulatory role of metalloproteinase ADAM17 in tumor development.

Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H Front Immunol. 2022; 13:1059376.

PMID: 36466812 PMC: 9715963. DOI: 10.3389/fimmu.2022.1059376.


Mechanobiological Implications of Cancer Progression in Space.

Kim H, Shin Y, Kim D Front Cell Dev Biol. 2021; 9:740009.

PMID: 34957091 PMC: 8692837. DOI: 10.3389/fcell.2021.740009.


Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells.

Guttler A, Eiselt Y, Funtan A, Thiel A, Petrenko M, Kessler J Int J Mol Sci. 2021; 22(16).

PMID: 34445506 PMC: 8395940. DOI: 10.3390/ijms22168808.


References
1.
Pastorekova S, Parkkila S, Parkkila A, Opavsky R, ZelnIk V, Saarnio J . Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997; 112(2):398-408. DOI: 10.1053/gast.1997.v112.pm9024293. View

2.
Pastorekova S, Parkkila S, Pastorek J, Supuran C . Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004; 19(3):199-229. DOI: 10.1080/14756360410001689540. View

3.
Hektoen H, Flatmark K, Andersson Y, Dueland S, Redalen K, Ree A . Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer. 2015; 15:543. PMC: 4513373. DOI: 10.1186/s12885-015-1557-6. View

4.
Ledaki I, McIntyre A, Wigfield S, Buffa F, McGowan S, Baban D . Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget. 2015; 6(23):19413-27. PMC: 4637295. DOI: 10.18632/oncotarget.4989. View

5.
Zatovicova M, Tarabkova K, Svastova E, Gibadulinova A, Mucha V, Jakubickova L . Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 2003; 282(1-2):117-34. DOI: 10.1016/j.jim.2003.08.011. View